# Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas

> **NCT00869284** · PHASE2 · COMPLETED · sponsor: **French Innovative Leukemia Organisation** · enrollment: 45 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** CEEP regimen
- **PROCEDURE:** Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)

## Key facts

- **NCT ID:** NCT00869284
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-10
- **Primary completion:** 1999-07
- **Final completion:** 2009-02
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2009-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00869284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00869284, "Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00869284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*